*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Modular Medical, Inc. (Nasdaq: MODD)
MODD is our brand new NASDAQ high-growth alert.
This is a hidden gem opportunity that not many have seen and we are amongst the first to bring it to your attention.
Plus, the company just crossed the single most important milestone a medical device company can reach, it received FDA clearance and has now transitioned from development stage to a commercial company delivering its product to real patients.
The chart setup is pointing to a potential breakout opportunity.
This means that momentum can build very quickly.
MODD is a NASDAQ listed “commercial-stage medical device company that is commercializing the next generation of insulin delivery technology”.
Using its “patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn”.
Its mission is “to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."”
The company’s flagship product is the Pivot, “designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems”.
“Pivot is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems.”
This group, “which the Company calls the "almost-pumpers," represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.”
“The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction.”
As “only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with.”
“Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required - all while maintaining clinical accuracy and connectivity.”
The pedigree here stands out. MODD was “founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump.”
The market opportunity is substantial. According to the company's investor presentation, its flagship Pivot pump targets a “$3 Billion unmet market need”
The company describes this underserved market clearly:
1 in 4 Healthcare dollars in the US are spent on diabetes and diabetes related complications
27 million people with diabetes. 4.88 million require daily insulin
Only 1 in 3 Americans with type 1 diabetes use a pump. This number has been materially unchanged for 15 years.
Only 20% of insulin dependent people with diabetes use a pump for insulin delivery. 80% rely on multiple daily injections (MDI).
Only 8% of insulin dependent Americans with type 2 diabetes use a pump. This number is just starting to rise.
Only 21% of T1D’s reach ADA guidelines for glycemic control.
The reason so many remain on injections comes down to what the company describes as “feature-heavy and complex systems have hampered adoption. These products are for “superusers.” Prohibitive for many to learn and manage.”
The company also points to a powerful precedent: “Abbott Freestyle Libre made continuous glucose monitoring easier and more affordable. This expanded the product category and doubled its size.”
They “believe the insulin pump market is ready for a similar transition.”
The company has announced multiple major milestones recently.
On April 9, the company announced big news:
“Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump”
“First Removable 2-Part Design Targets $3 Billion "Almost-Pumper" Market with Expected Q2 2026 initial deployment.”
Key Milestones & Investment Highlights:
“FDA 510(k) Clearance Achieved: Pivot™ pump now cleared for commercial sale in the U.S. - major de-risking event unlocking revenue path.
First-in-Class Removable Tubeless Patch Pump: 3 mL detachable reservoir; no battery recharging required; removable for showering, sports or discretion; quick bolus button without a separate controller.
Targets Massive Underserved Market: ~70% of insulin-dependent adults remain on multiple daily injections (MDI) due to complexity, cumbersomeness and cost - Pivot addresses the "3 Cs" for "almost-pumpers" with its 2-part reusable pump.
Manufacturing Readiness: Production validation lots well underway; initial capacity supports ~6,000 users with scalable low-cost platform enabling a rapid production ramp-up.
Commercial Timeline: Initial customers expected by end of Q2 2026; software enhancements (e.g., variable bolus, improved alarms, ACE/AID compatibility) in development; CE Mark targeted Q4 2026/Q1 2027.”
Jeb Besser, CEO of Modular Medical, said:
"FDA clearance for Pivot represents years of focused innovation to deliver a truly differentiated tubeless patch pump. By addressing the key barriers - complexity, bulkiness, and high cost - we believe we are positioned to convert millions still on injections to pump therapy. With manufacturing on track and our software roadmap advancing toward automated insulin delivery ("AID") features, we believe this clearance significantly de-risks our commercial launch and opens a clear path to capturing share in the growing diabetes technology market.
"We thank our team, stakeholders, and shareholders for their support. We now shift focus to our rapid commercialization strategy, additional software enhancements, and European CE Mark progress in the second half of 2026. We look forward to providing operational and adoption updates in the coming months."
In April, the company also announced:
“Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock”
In June, the company announced:
“Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion”
“Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across multiple metropolitan markets by late 2026.”
Here are some of the company’s comments from this press release:
"Reaching commercial availability is a transformational milestone that marks Modular Medical's transition from a development-stage company to a revenue-generating commercial business," said Jeb Besser, Chief Executive Officer of Modular Medical. "As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved 'almost-pumper' population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders."
On June 26, 2026, the company announced:
“Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps”
“Pivot starter kits are now shipping to multiple endocrinology practices”
This is another “significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin.”
Most recently, on June 30, the company announced:
“Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch Pump”
Here are some of the company’s comments from this press release:
"Today represents a defining moment for Modular Medical," said Jeb Besser, Chief Executive Officer of Modular Medical. "For the first time, patients are using Pivot to manage their insulin therapy, validating our vision of creating a simpler, more accessible pump solution for people who have historically remained on multiple daily injections. This is only the beginning of our efforts to address this substantial market opportunity, and we look forward to gathering real-world data and feedback, as we seek to scale adoption and achieve long-term growth."
On July 1, the company announced:
“Modular Medical Announces FDA Submission of Pivot Tubeless Insulin Patch Pump Enhancements”
"This submission is the first of a series of further improvements and upgrades planned for the Pivot platform, now that our core form factor has been cleared by the FDA and is in the market. I want to congratulate our whole team for getting this submission in so quickly after the initial Pivot clearance," said Jeb Besser, Chief Executive Officer of Modular Medical. "We look forward to getting feedback from the FDA in the coming weeks."
But that’s not all…
Yesterday the company announced breaking news:
“Modular Medical Announces Completion of Research Initiative Indicating Strong Interest in Simpler Insulin Delivery”
“97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes
Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump
Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026”
In addition, just this morning, the company announced:
“Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump”
“Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot”
We believe MODD could be positioned for big upside potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 7/8/26 for the distribution of this advertisement about MODD dated 7/15/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.